- Home
- USEA vs LITS Comparison
USEA vs LITS Comparison
Compare USEA & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USEA | LITS |
|---|---|---|
| Founded | 2004 | 2000 |
| Country | Greece | United States |
| Employees | N/A | 4 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7M | 25.7M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | USEA | LITS |
|---|---|---|
| Price | $2.71 | $0.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 44.3K | ★ 135.2K |
| Earning Date | 05-21-2026 | 05-19-2026 |
| Dividend Yield | ★ 11.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.55 | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $0.69 |
| 52 Week High | $2.82 | $3.03 |
Technical Indicators
Market Signals| Indicator | USEA | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 58.78 | 44.55 |
| Support Level | $2.48 | $0.79 |
| Resistance Level | $2.78 | $0.99 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 77.14 | 16.10 |
Price Performance
Historical ComparisonAbout USEA United Maritime Corporation
United Maritime Corp is an international shipping company currently specializing in world-wide seaborne transportation services. It currently operates a fleet of dry bulk vessels, comprising Panamax, Capesize and Kamsarmax vessels. Its vessels include Dukeship, Nisea, Cretansea, Chrisea, Synthesea, and Exelixsea.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.